Children's Medical Center, China Medical University Hospital, China Medical University, Taichung, Taiwan.
J Pediatr. 2010 Mar;156(3):393-6. doi: 10.1016/j.jpeds.2009.09.051. Epub 2009 Nov 14.
To evaluate growth and neurodevelopmental outcomes in preterm very low birth weight (PVLBW) infants treated with oral probiotics for the prevention of necrotizing enterocolitis (NEC).
A prospective follow-up study was performed in a cohort of PVLBW infants enrolled in a single center with a masked randomized control trial to evaluate the efficacy of oral probiotics in preventing NEC. Growth measures included weight, length, and head circumference. Neurologic and sensory performance was evaluated with standard techniques. Psychometric parameters were measured used the Bayley Scales of Infant Development II (BSID-II). The studies were performed at 3 years corrected age. The primary outcome was death or neurodevelopmental impairment.
Of the 367 subjects enrolled in trial, 301 (89.9%) were evaluated (153 in the probiotics group and 148 in the control group). There were no significant differences in growth or in any of the neurodevelopmental and sensory outcomes between the 2 groups.
Oral probiotics given to PVLBW infants at 1 week after birth to reduce the incidence of NEC did not affect growth and neurodevelopmental and sensory outcomes at 3 years corrected age.
评估口服益生菌预防坏死性小肠结肠炎（NEC）治疗的早产儿极低出生体重儿（PVLBW）的生长和神经发育结局。
在一项单中心的前瞻性随访研究中，对接受口服益生菌预防 NEC 的 PVLBW 婴儿进行了一项盲法随机对照试验，以评估口服益生菌的疗效。生长指标包括体重、身长和头围。神经和感觉功能采用标准技术进行评估。使用贝利婴幼儿发展量表第二版（BSID-II）进行心理计量学参数测量。研究在矫正年龄 3 岁时进行。主要结局为死亡或神经发育障碍。
在试验中纳入的 367 例受试者中，有 301 例（89.9%）进行了评估（益生菌组 153 例，对照组 148 例）。两组之间在生长或任何神经发育和感觉结局方面均无显著差异。
在出生后 1 周给予 PVLBW 婴儿口服益生菌以降低 NEC 的发生率，不会影响 3 岁矫正年龄时的生长和神经发育及感觉结局。
